Beta-2 Microglobulin and Serum Cytokines x HAART

UPECLIN HC FM Botucatu Unesp

Status

Completed

Conditions

HIV Patients

Study type

Observational

Funder types

Other

Identifiers

NCT00831207

upeclin/HC/FMB-Unesp-19

Details and patient eligibility

About

Cross-sectional study to assess the behavior of Beta-2 microglobulin and serum cytokines TNF-α, IFN-γ, IL-2, IL-4 and IL-10 as indicators of highly active antiretroviral therapy (HAART) failure.

Full description

Objective: To assess the behavior of Beta-2 microglobulin and serum cytokines TNF-α, IFN-γ, IL-2, IL-4 and IL-10 as indicators of highly active antiretroviral therapy (HAART) failure Design: Cross-sectional study. Methods: Eighty-nine HIV-1+ patients and 20 normal individuals were divided into 4 groups: G1- 15 HIV-1+ individuals, previously untreated or without HAART for at least six months and CD4+ < 350 cells/mm3; G2- 31 HIV-1+ individuals undergoing HAART without virological therapeutic failure (TF), G3- 43 HIV-1+ individuals undergoing HAART with TF, and GC- 20 normal individuals who served as controls for serum cytokines. Demographic, clinical and HAART data were reviewed, and Beta-2 microglobulin, serum cytokines (TNF-α, IFN-γ, IL-2, IL-4 and IL-10), HIV-1 genotyping, plasma viral load and CD4+ and CD8+ lymphocytes tests were performed.

Key words: Beta-2 microglobulin, serum cytokines, HIV-1, resistance, HAART, therapeutic failure, genotyping.

Enrollment

109 patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

HIV-1-infected individuals
Over 18 years old
Sign the "written consent form" (WCF)

Exclusion criteria

Do not presenting other immunosuppression causes, such as neoplasias, transplantations
Do not presenting treatment by immunosuppressive substances
Do not presenting auto-immune diseases
Not be using any type of immunostimulating substances
Not at any time of gestation